PMID- 21872138
OWN - NLM
STAT- MEDLINE
DCOM- 20120604
LR  - 20181201
IS  - 1532-8414 (Electronic)
IS  - 1071-9164 (Linking)
VI  - 17
IP  - 9
DP  - 2011 Sep
TI  - Comparative long term effects of nebivolol and carvedilol in hypertensive heart 
      failure patients.
PG  - 703-9
LID - 10.1016/j.cardfail.2011.05.001 [doi]
AB  - BACKGROUND: Beta-blockers improve left ventricular (LV) systolic function and 
      prognosis in patients with chronic heart failure (CHF), but their different 
      pleiotropic properties may influence their cardiovascular effects. This 
      open-label study compared the effects of long-term treatment with nebivolol 
      versus carvedilol on LV ejection fraction (LVEF), in hypertensive CHF patients. 
      Secondary end points were to assess the effect of the 2 beta-blockers on exercise 
      capacity and clinical outcome. METHODS AND RESULTS: A total of 160 hypertensive 
      CHF patients, with LVEF <40% and in New York Heart Association (NYHA) functional 
      class I, II, or III, were randomly assigned to receive nebivolol or carvedilol 
      for 24 months. At baseline and at the end of treatment, all patients underwent 
      clinical evaluation, echocardiography, and 6-minute walking test. The target 
      doses were 10 mg/d for nebivolol and 50 mg/d for carvedilol. Compared with 
      baseline values, LVEF increased by a similar extent in the carvedilol (C) and 
      nebivolol (N) groups (C from 36.1% (SD 1.5%) to 40.9% (SD 1.9%), P < .001; N from 
      34.1% (SD 1.8%) to 38.5% (SF 2.2%), P < .001). Heart rate and NYHA functional 
      class decreased significantly in both groups, and the 6-minute walking distance 
      increased (C from 420 m (SD 104 m) to 490 m (SD 115 m), P < .001; N from 421 m 
      (SD 118 m) to 487 m (SD 138 m), P < .001). During 24 months, 21 carvedilol 
      recipients (26%) and 18 nebivolol recipients (22%) had cardiac events, including 
      3 and 4 deaths, respectively. CONCLUSION: In the long term, nebivolol and 
      carvedilol appear to be similarly effective in the treatment of hypertensive 
      patients with CHF.
CI  - Copyright (c) 2011 Elsevier Inc. All rights reserved.
FAU - Marazzi, Giuseppe
AU  - Marazzi G
AD  - Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele, Rome, Italy. 
      giuseppe.marazzi@sanraffaele.it
FAU - Volterrani, Maurizio
AU  - Volterrani M
FAU - Caminiti, Giuseppe
AU  - Caminiti G
FAU - Iaia, Luigi
AU  - Iaia L
FAU - Massaro, Rosalba
AU  - Massaro R
FAU - Vitale, Cristiana
AU  - Vitale C
FAU - Sposato, Barbara
AU  - Sposato B
FAU - Mercuro, Giuseppe
AU  - Mercuro G
FAU - Rosano, Giuseppe
AU  - Rosano G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20110616
PL  - United States
TA  - J Card Fail
JT  - Journal of cardiac failure
JID - 9442138
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Benzopyrans)
RN  - 0 (Carbazoles)
RN  - 0 (Ethanolamines)
RN  - 0 (Propanolamines)
RN  - 030Y90569U (Nebivolol)
RN  - 0K47UL67F2 (Carvedilol)
SB  - IM
MH  - Aged
MH  - Antihypertensive Agents/*therapeutic use
MH  - Benzopyrans/*therapeutic use
MH  - Carbazoles/*therapeutic use
MH  - Carvedilol
MH  - Ethanolamines/*therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/complications/*drug therapy/physiopathology
MH  - Humans
MH  - Hypertension/complications/*drug therapy/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Nebivolol
MH  - Propanolamines/*therapeutic use
MH  - Prospective Studies
MH  - Single-Blind Method
MH  - Time Factors
EDAT- 2011/08/30 06:00
MHDA- 2012/06/05 06:00
CRDT- 2011/08/30 06:00
PHST- 2010/05/14 00:00 [received]
PHST- 2011/05/01 00:00 [revised]
PHST- 2011/05/03 00:00 [accepted]
PHST- 2011/08/30 06:00 [entrez]
PHST- 2011/08/30 06:00 [pubmed]
PHST- 2012/06/05 06:00 [medline]
AID - S1071-9164(11)00198-9 [pii]
AID - 10.1016/j.cardfail.2011.05.001 [doi]
PST - ppublish
SO  - J Card Fail. 2011 Sep;17(9):703-9. doi: 10.1016/j.cardfail.2011.05.001. Epub 2011 
      Jun 16.